Medical Genetics Laboratory, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy.
Am J Respir Cell Mol Biol. 2013 May;48(5):619-25. doi: 10.1165/rcmb.2012-0371OC.
Splicing mutations account for approximately 12% of the 1,890 cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations described in cystic fibrosis (CF). However, their impact on pre-mRNA processing frequently remains unclear. An interesting opportunity to study CFTR transcripts in vivo involves the use of RNA from nasal brushings. Through this approach we previously identified a deep-intronic mutation (c.1584+18672A>G) that activates a 104-base pair (bp) out-of-frame pseudoexon by creating a donor splice site. The screening of 230 patients with CF identified c.1584+18672A>G in three additional individuals, demonstrating that it is a recurrent, and potentially overlooked, mutation among Italian patients. Haplotype analysis suggests that it originated from at least two independent events. To characterize the mutation further, a genomic region, including the activated pseudoexon and surrounding intronic sequences, was cloned into an expression vector and transfected into HeLa cells. RT-PCR analysis identified two alternative splicing products, produced by the activation of two different cryptic acceptor splice sites. One included the 104-bp pseudoexon (78.7% of transcripts), and the other led to the inclusion of a 65-bp pseudoexon (21.3% of mRNAs). The allele-specific measurement of wild-type and aberrant splicings from the nasal-brushing RNA of the three probands with genotype F508del/c.1584+18672A>G demonstrated: (1) a low level of pseudoexon inclusion in the F508del transcript (not containing the splicing mutation); (2) residual wild-type splicing in the c.1584+18672A>G mRNA; (3) the degradation of aberrant transcripts; and (4) the relative strength of the different cryptic splice sites. Interestingly, the residual wild-type splicing detected in transcripts bearing the c.1584+18672A>G mutation correlates well with the milder clinical phenotype of patients.
剪接突变约占囊性纤维化跨膜电导调节因子 (CFTR) 基因 1890 种突变中 12%,这些突变在囊性纤维化 (CF) 中描述。然而,它们对前体 mRNA 加工的影响常常不清楚。一个有趣的研究 CFTR 转录本的机会是使用鼻腔刷取物中的 RNA。通过这种方法,我们之前鉴定了一个深内含子突变 (c.1584+18672A>G),通过创建供体位点激活了一个 104 个碱基对 (bp) 的无义假外显子。在 230 名 CF 患者的筛选中,在另外 3 名个体中发现了 c.1584+18672A>G,表明它是意大利患者中一种反复出现且可能被忽视的突变。单倍型分析表明,它至少起源于两个独立的事件。为了进一步表征突变,我们将包括激活的假外显子和周围内含子序列的基因组区域克隆到表达载体中,并转染到 HeLa 细胞中。RT-PCR 分析鉴定了两种由两个不同的隐蔽受体剪接位点激活产生的选择性剪接产物。一种包括 104-bp 的假外显子 (78.7%的转录物),另一种导致包含 65-bp 的假外显子 (21.3%的 mRNA)。对三个基因型为 F508del/c.1584+18672A>G 的先证者的鼻腔刷 RNA 中野生型和异常剪接的等位基因特异性测量表明:(1) 在不包含剪接突变的 F508del 转录物中假外显子的插入水平低;(2) 在 c.1584+18672A>G mRNA 中残留的野生型剪接;(3) 异常转录物的降解;和 (4) 不同隐蔽剪接位点的相对强度。有趣的是,在携带 c.1584+18672A>G 突变的转录物中检测到的残留野生型剪接与患者较轻的临床表型密切相关。